IRIS
TAGLIAMENTO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.590
Totale 2.590
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.590
Totale 2.590
Salva come PNG Salva come JPEG
Città #
Genova 927
Vado Ligure 629
Genoa 546
Rapallo 474
Bordighera 14
Totale 2.590
Salva come PNG Salva come JPEG
Nome #
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 118
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 116
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 101
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 99
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 89
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 89
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 83
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 77
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 75
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 75
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 74
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 65
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 62
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 62
Update on the management of breast cancer during pregnancy 61
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 60
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 58
Radiomic detection of EGFR mutations in NSCLC 57
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 57
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 55
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 54
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 52
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 52
Call for ensuring cancer care continuity during COVID-19 pandemic 52
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 50
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 50
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab 48
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 45
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies 43
Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient 43
Novel emerging molecular targets in non-small cell lung cancer 43
Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women 42
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 41
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 39
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 36
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 35
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 32
Performance of the oncomineTM Lung cfDNA assay for liquid biopsy by NGS of NSCLC patients in routine laboratory practice 30
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 30
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis” 20
Expected medium- And long-term impact of the COVID-19 outbreak in oncology 20
VISTA: A Promising Target for Cancer Immunotherapy? 20
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 19
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 19
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 18
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 18
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 17
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates 16
The evolving scenario of cancer care provision across the COVID-19 pandemic in Europe 15
Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer 15
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 14
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer 14
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 14
Does perioperative immunotherapy reduce the risk of second primary cancers? 14
Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction 13
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study 12
Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity 12
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 11
Heterogeneity of treatment effects in malignant pleural mesothelioma 11
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 11
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 10
New emerging targets in cancer immunotherapy: The role of VISTA 10
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors 10
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 8
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test 8
The use of immunotherapy in older patients with advanced non-small cell lung cancer 7
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 7
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey 7
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 7
Oncological care organisation during COVID-19 outbreak 7
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 7
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 6
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma 5
Totale 2.772
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.304
article - articoli 15.238
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020133 0 0 0 0 0 23 20 24 14 24 23 5
2020/2021432 12 26 27 64 123 18 12 38 31 47 12 22
2021/2022394 38 13 9 29 21 25 16 79 32 52 21 59
2022/2023566 43 53 5 48 93 81 7 45 97 12 75 7
2023/2024475 11 33 11 55 27 85 36 36 17 42 39 83
2024/2025712 78 101 43 115 220 155 0 0 0 0 0 0
Totale 2.772